If you read this article, you know that Genentech was set to release new pivotal data from its "extensive" hematology portfolio from December 11-14, 2021, at ASH 2021 (American Society of Hematology). Of the three studies that Genentech presented, is HAVEN 6 phase III interm data of Emicizumab, which is widely known as HEMLIBRA.
Hemlibra (Emicizumab) is a subcutaneous injection and treatment for patients concerning Hemophilia A. It was developed by Genentech and Chugai and was approved in the United States in November of 2017. Learn more about HEMLIBRA here.
The Phase III interm data included 71 patients, 69 of them being male. 20 participants had mild hemophilia A without inhibitors and 50 had moderate hemophilia A without inhibitors. 37 participants were on prophylaxis (Factor VIII), at the baseline of the study.
Also Read - What is Hemlibra?
In the phase III HAVEN 6 study, 80.3% of the patients experienced zero bleeding episodes that required treatment and 90.1% experienced zero joint bleeding episodes that required treatment. The annualized bleeding rates (ABR) among the participants remained consistent with the reported observations in the HAVEN 1-4 studies. “We are pleased to see that Hemlibra continues to show benefit in additional hemophilia A populations, regardless of severity,” said Levi Garraway who is the chief medical officer and the head of Global Product Development at Genentech.
Right now, HEMLIBRA is approved in over 100 countries and has been tried in 8 phase III studies. Want to read more about the study? Click here.
Want to learn more about bleeding disorders? Sign up for our newsletter here! SIGN UP
Commentaires